

( (S -LRB-
     (PP-TMP During
	     (NP its centennial year))
     ,
     (NP-SBJ The Wall Street Journal)
     (VP will
	 (VP report
	     (NP (NP events)
		 (PP of
		     (NP the past century))
		 (SBAR (WHNP-1 that)
		       (S (NP-SBJ *T*-1)
			  (VP stand
			      (PP-CLR as
				      (NP (NP milestones)
					  (PP of
					      (NP American business history))))))))))
     .
     -RRB-))
( (S-HLN (NP-SBJ-1 LUTHER BURBANK)
	 (VP CROSS-BRED
	     (NP PLANTS)
	     (S-PRP (NP-SBJ *-1)
		    (VP to
			(VP produce
			    (NP the billion-dollar Idaho potato)))))
	 .))
( (S (NP-SBJ-1 Bioengineers)
     (VP set
         (PRT out)
         (S-CLR (NP-SBJ *-1)
		(VP to
		    (VP duplicate
			(NP that feat)
			(PRN --
			     (ADVP-MNR scientifically
				       and
				       commercially)
			     --)
			(PP-MNR with
				(NP new life forms))))))
     .))
( (S (PP-TMP In
	     (NP 1953))
     ,
     (NP-SBJ (NP James Watson)
             and
             (NP his colleagues))
     (VP unlocked
         (NP (NP the double helix)
	     (PP of
		 (NP (NP DNA)
		     (PRN -LRB-
			  (NP deoxyribonucleic acid)
			  -RRB-)
		     ,
		     (NP (NP the genetic key)
			 (PP to
			     (NP heredity)))))))
     .))
( (S (ADVP-TMP (NP Twenty years) later)
     ,
     (NP-SBJ-1 (NP two California academics)
	       ,
	       (NP (NP Stanley Cohen)
		   and
		   (NP Herbert Boyer))
	       ,)
     (VP made
         (NP `` recombinant '' DNA)
         ,
         (S-ADV (NP-SBJ *-1)
		(VP transplanting
		    (NP (NP a toad 's)
			gene)
		    (PP-CLR into
			    (NP (NP bacteria)
				,
				(SBAR (WHNP-104 which)
				      (S (ADVP-TMP then)
					 (NP-SBJ *T*-104)
					 (VP reproduced
					     (NP toad genes)))))))))
     .))
( (S (SBAR-TMP (WHADVP-1 When)
	       (S (NP-SBJ Boyer)
		  (VP met
		      (NP (NP Robert Swanson)
			  ,
			  (NP an M.I.T.-trained chemist-turned-entrepreneur))
		      (PP-TMP in
			      (NP 1976))
		      (ADVP-TMP *T*-1))))
     ,
     (NP-SBJ they)
     (VP saw
         (NP dollar signs))
     .))
( (S (PP With
         (NP (NP (NP $ 500 *U*) 
		 (ADVP apiece))
             and
             (NP (NP an injection)
                 (PP of
                     (NP outside capital)))))
     ,
     (NP-SBJ they)
     (VP formed
         (NP Genentech Inc))
     .))
( (S (NP-SBJ-1 Commercial gene-splicing)
     (VP was
         (VP born
	     (NP *-1)))
     .))
( (S (NP-SBJ (NP (NP Genentech 's)
                 first product)
             ,
             (NP (NP a brain protein)
                 (VP called
		     (S (NP-SBJ *)
			(NP-PRD somatostatin))))
             ,)
     (VP proved
         (NP its technology))
     .))
( (S (S (NP-SBJ (NP The next)
		(SBAR (WHNP-1 0)
		      (S (NP-SBJ-2 *T*-1)
			 (VP to
			     (VP be
				 (VP cloned
				     (NP *-2))))))
                ,
                (NP human insulin)
                ,)
        (VP had
            (NP market potential)))
     and
     (S (NP-SBJ Genentech)
        (VP licensed
            (NP it)
            (PP-CLR to
		    (NP (NP Eli Lilly)
			,
			(SBAR (WHNP-105 which)
			      (S (NP-SBJ *T*-105)
				 (VP produced
				     (NP (NP 80 %)
					 (PP of
					     (NP (NP the insulin)
						 (VP used
						     (NP *)
						     (PP by
							 (NP-LGS (QP 1.5 million)
								 U.S. diabetics)))))))))))))
     .))
( (S (S (NP-SBJ Their laboratory credentials)
	(VP established
	    (NP *)))
     ,
     (NP-SBJ Boyer
             and
             Swanson)
     (VP headed
         (PP-DIR for
		 (NP Wall Street))
         (PP-TMP in
		 (NP 1980)))
     .))
( (S (PP-TMP At
	     (NP the time))
     ,
     (NP-SBJ Genentech)
     (VP had
         (NP (NP (NP (NP only one profitable year)
                     (PP behind
                         (NP it)))
                 (PRN -LRB-
		      (NP (NP a modest $ 116,000 *U*)
			  (PP on
			      (NP (NP revenue)
				  (PP of
				      (NP (QP $ 2.6 million) *U*))
				  (PP-TMP in
					  (NP 1979)))))
		      -RRB-))
             and
             (NP (NP no product)
                 (PP of
                     (NP its own))
                 (PP-LOC on
			 (NP the market)))))
     .))
( (S (ADVP Nonetheless)
     ,
     (NP-SBJ (NP the (ADJP (QP $ 36 million) *U*) issue)
             (SBAR (WHNP-1 0)
                   (S (NP-SBJ they)
                      (VP floated
			  (NP *T*-1)
                          (PP-TMP in
				  (NP 1980))))))
     (VP (VP opened
             (PP-CLR at
		     (NP $ 35 *U*)))
         and
         (VP leaped
             (PP-DIR to
		     (NP $ 89 *U*))
             (PP-TMP within
		     (NP 20 minutes))))
     .))
( (S (NP-SBJ (NP The trip)
             (PP from
		 (NP the test tube)))
     (VP was not
         (PP-PRD without
		 (NP snags)))
     .))
( (S (S (NP-SBJ-1 (NP Boyer and Cohen)
		  (PRN ,
		       (PP for
			   (NP instance))
		       ,)
		  (NP both still university researchers)
		  ,)
        (VP had
            (S (NP-SBJ-2 *-1)
               (VP to
		   (VP be
		       (VP talked
			   (NP *-2)
			   (PP-CLR into
				   (S-NOM (NP-SBJ *)
					  (VP applying
					      (PP-CLR for
						      (NP (NP a patent)
							  (PP-LOC on
								  (NP their gene-splicing technique)))))))))))))
     -- 
     and 
     (ADVP-TMP then)
     (S (NP-SBJ-3 the Patent Office)
        (VP refused
            (S (NP-SBJ *-3)
               (VP to
                   (VP grant
                       (NP it))))))
     .))
( (S (NP-SBJ-1 That judgment)
     ,
     (PP in
         (NP turn))
     ,
     (VP was
         (VP reversed
	     (NP *-1)
             (PP by
                 (NP-LGS the U.S. Supreme Court))
             ,
             (S-ADV (NP-SBJ *)
		    (VP leaving
			(S (NP-SBJ Cohen
				   and
				   Boyer)
			   (VP holding
			       (NP (NP (NP the first patents)
				       (PP for
					   (S-NOM (NP-SBJ *)
						  (VP making
						      (NP recombinant DNA)))))
				   (PRN -LRB-
					(VP (ADVP-TMP now)
					    assigned
					    (PP-CLR to
						    (NP their schools)))
					-RRB-))))))))
     .))
( (S (NP-SBJ Gene-splicing)
     (ADVP-TMP now)
     (VP is
         (NP-PRD (NP an integral part)
		 (PP of
		     (NP the drug business))))
     .))
( (S (NP-SBJ (NP Genentech 's)
             1988 sales)
     (VP were
         (NP-PRD (QP $ 335 million) *U*)
         ,
         (PP both 
	     from
             (NP licensing)
             and
             (NP its own products)))
     .))
